Health care stocks were softer Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) both down 0.4%.
The iShares Biotechnology ETF (IBB) rose 0.5%.
In corporate news, Merck (MRK) issued a downbeat full-year outlook, overshadowing stronger-than-expected Q4 results. The shares fell past 10%.
Pfizer's (PFE) Q4 results topped market expectations amid double-digit revenue growth across key segments, while the pharmaceutical giant reiterated its full-year outlook. Its shares were down 1.7%.
Novartis (NVS) is on the hunt for next-generation obesity drug candidates, despite its main focus remaining on therapeutic areas where it has an established presence, The Wall Street Journal reported Tuesday, citing an interview with Chief Executive Vasant Narasimhan. Novartis shares were fractionally lower.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。